When Will Malaria Meds Stop Working In Africa?

Malaria drugs are losing their power in Africa—and experts say the continent should treat it as an emergency. The warning comes as evidence mounts that artemisinin-based combination therapies (ACTs), the frontline treatment for Plasmodium falciparum malaria, are showing reduced efficacy in parts of East Africa. The quote from a leading malaria researcher underscores the gravity: “The continent should take the matter of resistance very, very seriously...Resistance should be seen as an emergency situation.”

The threat is not new—artemisinin resistance first emerged in Southeast Asia over a decade ago, forcing health authorities to switch to alternative regimens. But its arrival in Africa, where more than 90% of the world's 619,000 annual malaria deaths occur, marks a potential catastrophe. In 2025, studies published in the New England Journal of Medicine confirmed partial resistance to artemisinin in Rwanda and Uganda, with subsequent reports from Ethiopia and parts of the Democratic Republic of Congo. The World Health Organization (WHO) now lists Africa as a high-priority region for resistance surveillance.

The mechanism behind the resistance is a mutation in the Pfkelch13 gene, which slows the parasite's clearance from the blood. When combined with partner drugs in ACTs, the failure rates can climb. In some Ugandan districts, treatment failure for dihydroartemisinin-piperaquine reached 15% in 2025—a threshold that prompts WHO to recommend a change in first-line therapy. African health systems, already strained by funding gaps and competing priorities, face a daunting task: track resistance, switch drug policies, and invest in new treatments.

Key organisations are mobilising. The Africa Centres for Disease Control and Prevention (Africa CDC) launched the “End Malaria Campaign 2.0” in 2024, prioritising resistance monitoring. The Medicines for Malaria Venture (MMV) is pushing forward triple ACTs—combinations like artemisinin + lumefantrine + amodiaquine—that can overcome partial resistance. However, clinical trials remain small-scale, and regulatory approvals may take years. Meanwhile, the WHO has urged countries to expand seasonal malaria chemoprevention (SMC) and vector control to reduce the parasite burden.

The broader implications are severe. If malaria drug resistance in Africa becomes widespread, the gains of the past two decades—a 36% drop in global malaria mortality since 2000—could be reversed. Children under five and pregnant women, who bear the brunt of the disease, would be most vulnerable. Economic productivity in endemic countries would suffer, and health systems would face further strain. As one analysis noted, “We are in a race against the parasite, and we are losing ground.”

What happens next hinges on three milestones. First, the WHO’s updated guidelines on resistance monitoring are expected in late 2026. Second, the rollout of triple ACTs in pilot regions of Uganda and Rwanda will produce real-world data. Third, funding decisions by the Global Fund and the US President’s Malaria Initiative will determine whether surveillance networks expand. Until then, the emergency alert stands: the window for action is closing, and Africa’s fight against malaria faces its gravest test yet.